ArticlePloS one2006
A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
Article in PloS one, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Medicare Part D and Hospital Admissions due to Antimicrobial Resistance.Health economics · 2026Article
- Antimicrobial Resistance and the Blood-Brain Barrier: Complex Interactions and Implications for Neurological Health.Molecular neurobiology · 2025Review
- The Prevalence of the Virulence Genes ofAntibiotics (Basel, Switzerland) · 2023Article
- LEGO-Lipophosphonoxins: A Novel Approach in Designing Membrane Targeting Antimicrobials.Journal of medicinal chemistry · 2022Article
- Antimicrobial and anti-biofilm activities of Bi subnitrate and BiNPs produced byIET nanobiotechnology · 2019Article
- Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics.Frontiers in microbiology · 2016Review
- Fighting microbial drug resistance: a primer on the role of evolutionary biology in public health.Evolutionary applications · 2015Article
- Effects of antibiotic physicochemical properties on their release kinetics from biodegradable polymer microparticles.Pharmaceutical research · 2014Article
- Schizophrenia--time to commit to policy change.Schizophrenia bulletin · 2014Article
- Antibiotic prescribing in women during and after delivery in a non-teaching, tertiary care hospital in Ujjain, India: a prospective cross-sectional study.Journal of pharmaceutical policy and practice · 2013Article
- Bismuth oxide aqueous colloidal nanoparticles inhibit Candida albicans growth and biofilm formation.International journal of nanomedicine · 2013Article
- Mining MEDLINE for the treatment of osteoporosis.Journal of medical systems · 2012Article
- Zerovalent bismuth nanoparticles inhibit Streptococcus mutans growth and formation of biofilm.International journal of nanomedicine · 2012Article
- Combating antimicrobial resistance: policy recommendations to save lives.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2011Article
- The potential of antimicrobial peptides as biocides.International journal of molecular sciences · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug treatment is becoming more expensive due to the increased cost for the introduction of new drugs, and there seems to be an uneven distribution of medication cost for different therapeutic categories. We hypothesized that the cost of new antimicrobial agents may differ from that of other therapeutic categories and this may play a role in the stagnation of development of new antibiotics. METHODOLOGY/PRINCIPAL
findingsWe performed a pharmaco-economical comparative analysis of the drug cost of treatment for new agents introduced in the United States drug market in various therapeutic categories. We calculated the drug cost (in US dollars) of a ten-day treatment of all new drugs approved by the FDA during the period between January 1997 and July 2003, according to the 2004 Red Book Pharmacy's Fundamental Reference. New anti-neoplastic agents were found to be the most expensive drugs in comparison to all other therapeutic categories, with a median ten-day drug-treatment cost of US$848 compared to the median ten-day drug-treatment costs of all other categories ranging from US$29 to US$301. On the other hand, new antimicrobial drugs were found to be much less expensive, with a median ten-day drug-treatment cost of US$137 and $US85 for all anti-microbial agents and for anti-microbial agents excluding anti-HIV medications, respectively. CONCLUSIONS/SIGNIFICANCE: The drug-treatment cost of new medications varies considerably by different therapeutic categories. This fact may influence industry decisions regarding the development of new drugs and may play a role in the shortage of new antimicrobial agents in the fight against the serious problem of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.